RE: New distributor?3 Apr 2025 11:48
Https://www.nw-gmsa.nhs.uk/application/files/8117/4367/0819/Issue_10__April_2025__GENOMICS_IN_PRACTICE_NEWSLETTER_GENERAL_PRACTICE_1.pdf
Update on the PROGRESS study
The PROGRESS study explores how pharmacogenomic testing can be implemented in primary care. Pharmacogenomics uses genetic information to improve medication safety and effectiveness, reducing adverse drug reactions and enhancing patient outcomes.
Phase I achievements
Recruitment began in 2023 in a small number of GP surgeries in the
NW region. Patients provide a saliva sample, which is analysed at the NHS NW Genomic Laboratory Hub.
The results are sent back to the primary care team within 7 to 10 working days, enabling clinicians to make more informed prescribing decisions.
Initially, the study invited patients taking selective serotonin reuptake inhibitors (SSRis), tricyclic antidepressants, statins, or PPls.
Later, codeine and tramadol were added to the trial protocol to broaden its scope.
Preliminary results showed that clinicians have received recommendations to alter prescribing decisions for 28% of patients, based on pharmacogenomic results. This highlights the significant potential of genetic testing to improve both medication safety and effectiveness.
Feedback from both clinicians and patients has been overwhelmingly positive. Participants and healthcare professionals expressed enthusiasm about the study's potential to improve clinical care.
Project expansion
The programme is now entering its second phase, which involves scaling up recruitment and expanding to more sites across England.
There are now more than 600 participants in this study.
A key development in this phase is the introduction of ProgressRx, an information solution that integrates pharmacogenomic test results and prescribing guidance directly into patients' electronic health records, which will streamline the process for clinicians, ensuring that pharmacogenomic information can be easily accessed and utilised at the point of prescribing.
Potential in the future
Jessica Keen, pharmacy lead at the NW GMSA said: "Success from the study would demonstrate the benefit of introducing pharmacogenomic testing into primary care and show that national implementation is both feasible and impactful."
This project is supported by NHS England through the Pharmacogenomics and Medicines Optimisation Genomic Network of Excellence, led by the NHS NW GMSA.
For more information on the PROGRESS research study, please visit our 'Spotlight' page.
Sign In
Follow the stocks
